BioLargo, Inc. (BLGO) stock
Close on Oct 19, 2026Market cap $23.27MP/E –Yield –
BioLargo, Inc. saw revenue fall 70.9% to $4.08M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $23.27M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $23.27M
- P/E ratio
- –
- Price to sales
- 5.70
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.08M
- EPS, diluted
- -$0.05
- Book value per share
- -$0.01
- Diluted shares
- 321M
Trading
- Previous close
- $0.07
- Open
- $0.07
- Day's range
- $0.07 – $0.07
- Volume
- 290,542
- Average volume (20 days)
- 435,304
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | BLGO | S&P 500 | Difference | BLGO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.6% | +0.6% | −21.2 pts | ||
| 3 months | -32.9% | +3.4% | −36.3 pts | ||
| Year to date | -60.7% | +13.3% | −73.9 pts | ||
| 1 year | -56.1% | +16.6% | −72.7 pts | ||
| 3 years | -59.7% | +86.4% | −146.1 pts | -26.1% | +23.1% |
| 5 years | -59.7% | +81.9% | −141.6 pts | -16.6% | +12.7% |
| 10 years | -89.9% | +318.9% | −408.8 pts | -20.5% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioLargo filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About BioLargo
Chemicals & Allied Products
BioLargo, Inc. invents, develops, and commercializes clean technologies addressing environmental and healthcare challenges. The company operates through distinct business units focused on air quality, water remediation, energy storage, professional engineering, and medical solutions. Its offerings include CupriDyne Clean odor and volatile organic compound control products, the Aqueous Electrostatic Concentrator for removing per- and polyfluoroalkyl substances, and the ViaCLYR wound management solution. Additionally, the company develops liquid sodium battery storage systems and provides multidisciplinary environmental engineering services. BioLargo serves municipalities, solid waste facilities, industrial clients, healthcare distributors, and governmental entities such as the United States Air Force.
Company profile, executives and historyBioLargo stock: common questions
What is BioLargo's stock price?
BLGO closed at $0.07 on Oct 19, 2026, up 0.90% on the day.
What is BioLargo's market cap?
BioLargo was worth $23.27M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is BLGO's P/E ratio?
BioLargo lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.05), so it has no meaningful P/E ratio.
How much revenue does BioLargo make?
BioLargo reported revenue of $4.08M for the twelve months to Jun 30, 2026, down 70.9% from a year earlier.
Does BioLargo pay a dividend?
No. BioLargo has not paid a cash dividend over the last twelve months.
How has BLGO stock performed over the past year?
Including dividends, BLGO returned -56.1% over the past year, against +16.6% for the S&P 500.
Who are BioLargo's competitors?
Companies most similar to BioLargo by business, industry and size include CITR, TOMZ, LQMT, LOOP, PURE.
See a number that looks wrong?